Two Houston entrepreneurs — Molly Voorhees (left) and Christina Milligan — have launched a new line of sanitizing products. Photo via instagram.com/cobaltclean

Houstonians Molly Voorhees and Christina Milligan have officially launched a line of hand sanitizing and surface cleaning products that blend the importance of cleanliness and safety with the added value of accessibility and a refined appearance.

The products make up the entrepreneurs' new brand, Cobalt, that Voorhees, president of Beck's Prime, and Milligan, an organizing and style expert, first conceptualized in March. As working parents of young children, the two women wanted to create a line of sanitizing products that boosted their confidence in the safety of their environments amid a pandemic and that they'd be proud to pull out of their purse on short notice.

"Cleaning products are in your bathroom or are in an ugly looking bottle or the back of our restaurant in massive chemical containers. There is really nothing for the on-the-go market," Voorhees says.

Too, the women didn't want to stop at hand sanitizer. Instead, they sought to encourage and educate clientele on the importance of cleaning high-touch surfaces, like phones, steering wheels, sunglasses, and the likes.

"It really resonated with us that your hands are only as clean as the surfaces that you touch," Milligan says. "We wanted it to be very approachable and easy to understand and also discrete. We didn't want anyone to feel ashamed if they pulled out a bottle of Lysol on a table."

The result was six FDA-approved sanitizers, sprays, keychains, and to-go kits that eliminate 99.9 percent of bacteria and viruses in easy to access, personal-sized, contemporary bottles, ranging from $14 to $30. The products are designed to be free of harsh, alcoholic odors and come in scents like peppermint and bubble gum.


The duo business women wanted to avoid harsh alcoholic smells and opted for calming and fun scents. Photo courtesy of Cobalt

Each item in the line boasts sleek, trendy designs in a cool blue hue. And while they look quite polished today, bringing the line to launch started off as a somewhat messy process.

"We kinda thought it would be easy. We would just put cleaner in a 4-ounce bottle and that would be fine," Milligan says.

But due to the high demand for chemical products in the pandemic and the way that industrial filling lines are set up, producing cleaning products in personal-sized bottles proved difficult. The women, who became known as the "the girls who want to put cleaner in their purse," were initially met with a resounding "no" from large chemical corporations.

However, by the summer the duo was able to make more headway. They were nearing production with a chemical partner when they learned of a local business who could produce their product by hand all within the Bayou City.

"It turned out through a connection we were making with labels that we discovered [William Price Distilling Company] that was right in our backyard in Houston that was newly filling bottles," Milligan says. "They were employing out of work restaurant staff. Molly and I both felt really strongly about that."

Voorhees and Milligan quickly partnered up with the Garden Oaks-Oak Forest distillery and have since produced roughly 2,500 units of their various products.

In fact, the line is decidedly Houston-based. In addition to William Price, Cobalt was also created with the help of Houston Labels for design. Deutser helped the team from a business management perspective. And the custom scents were developed by Clarity Fragrance near Memorial City.

As of press time, the products are available for purchase online and in area boutiques, including Emerson Sloan, Lexington Boutique, Zadok Jewelers, Therapy Hair Studio, and The Chocolate Bar. They aim to expand to more stores and markets and adapt the line based on demand.

"We feel so fortunate that we have a variety of products," Voorhees says. "It's always my belief that the consumer will tell you what they want and you go in that direction."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”